Level B· Emerging clinical evidence with positive signalsClinical TrialPubMedOpen access

Injection of Adipose-Derived Stromal Cells in the Knee of Patients with Severe Osteoarthritis has a Systemic Effect and Promotes an Anti-Inflammatory Phenotype of Circulating Immune Cells.

Pers YM., Quentin J., Feirreira R., Espinoza F., Abdellaoui N., Erkilic N.

Clinical Trial with a reported sample of 18 on Osteoarthritis, Chronic Inflammation, Immune Modulation, published in Theranostics (2018) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Theranostics (2018)
Country
Australia
Reported sample size
18
Source database
PubMed
PMID
30555561
PMCID
PMC6276295
DOI
10.7150/thno.27674
Citations
53

Abstract (original English)

Rationale: Recent studies confirmed that osteoarthritis (OA) is associated with systemic inflammation. Adipose-derived stromal cells (ASCs) could become the most promising cell-based therapy in OA, based not only on their differentiation capacities and trophic and paracrine effects on the existing cartilage, but also on their immunomodulatory properties. Here, we wanted to determine the biological effect of autologous ASC intra-articular (IA) injection. Method: To this aim, we monitored the profile of immune cells in fresh peripheral blood after IA injection of autologous ASCs in the knee of 18 patients with severe OA (ADIPOA phase I study). Specifically, we used 8-color flow cytometry antibody panels to characterize the frequencies of innate and adaptive immune cell subsets (monocytes, dendritic cells, regulatory T cells and B cells) in blood samples at baseline (before injection) and one week, one month and three months after ASC injection. Results: We found that the percentage of CD4 + CD25 high CD127 low FOXP3 + regulatory T cells was significantly increased at 1 month after ASC injection, and this effect persisted for at least 3 months. Moreover, CD24 high CD38 high transitional B cells also were increased, whereas the percentage of classical CD14 + monocytes was decreased, at 3 months after ASC injection. These results suggest a global switch toward regulatory immune cell

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipose TissueFlow CytometryHumansKnee JointMesenchymal Stem CellsOsteoarthritis, KneeProspective StudiesStromal Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research